Chemomab Therapeutics (CMMB) reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.
Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.
The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.
Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.
Shares of the company rose 1.5% in recent Monday trading.
Price: 1.33, Change: +0.02, Percent Change: +1.53
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。